Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
Identifieur interne : 001A27 ( Main/Exploration ); précédent : 001A26; suivant : 001A28Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
Auteurs : David P. Nichols [États-Unis] ; Michael W. Konstan [États-Unis] ; James F. Chmiel [États-Unis]Source :
- Clinical Reviews in Allergy & Immunology [ 1080-0549 ] ; 2008-12-01.
English descriptors
Abstract
Abstract: Cystic fibrosis (CF) is an autosomal recessive disease affecting many organ systems. In the lung, the underlying ion transport defect in CF establishes a perpetuating cycle of impaired airway clearance, chronic endobronchial infection, and exuberant inflammation. The interrelated nature of these components of CF lung disease makes it likely that the most effective therapeutic strategies will include treatments of each of these. This chapter reviews the preclinical and clinical data focused on ways to better understand and particularly to limit inflammation in the CF airway. Anti-inflammatories are an attractive therapeutic target in CF with a proven ability to decrease the rate of decline in lung function. However, the inherent complexity of the inflammatory response combined with the obvious dependency on this response to contain infection and the side effect profiles of common anti-inflammatories have made identifying the most suitable agents challenging. Research continues to discover impairments in signaling events in CF that may contribute to the excessive inflammation seen clinically. Concurrent with these findings, promising new therapies are being evaluated to determine which agents will be most effective and well tolerated. Available data from studies commenced over the last two decades, which have generated both encouraging and disappointing results, are reviewed below.
Url:
DOI: 10.1007/s12016-008-8081-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002929
- to stream Istex, to step Curation: 002929
- to stream Istex, to step Checkpoint: 000933
- to stream Main, to step Merge: 001A36
- to stream Main, to step Curation: 001A27
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease</title><author><name sortKey="Nichols, David P" sort="Nichols, David P" uniqKey="Nichols D" first="David P." last="Nichols">David P. Nichols</name></author><author><name sortKey="Konstan, Michael W" sort="Konstan, Michael W" uniqKey="Konstan M" first="Michael W." last="Konstan">Michael W. Konstan</name></author><author><name sortKey="Chmiel, James F" sort="Chmiel, James F" uniqKey="Chmiel J" first="James F." last="Chmiel">James F. Chmiel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F30D95A8911972350FDACACAB2A66387CE5DEDCA</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1007/s12016-008-8081-2</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-5345R921-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002929</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002929</idno><idno type="wicri:Area/Istex/Curation">002929</idno><idno type="wicri:Area/Istex/Checkpoint">000933</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000933</idno><idno type="wicri:doubleKey">1080-0549:2008:Nichols D:anti:inflammatory:therapies</idno><idno type="wicri:Area/Main/Merge">001A36</idno><idno type="wicri:Area/Main/Curation">001A27</idno><idno type="wicri:Area/Main/Exploration">001A27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease</title><author><name sortKey="Nichols, David P" sort="Nichols, David P" uniqKey="Nichols D" first="David P." last="Nichols">David P. Nichols</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Pulmonology, MS# 6006, Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, 44106, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Konstan, Michael W" sort="Konstan, Michael W" uniqKey="Konstan M" first="Michael W." last="Konstan">Michael W. Konstan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Pulmonology, MS# 6006, Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, 44106, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Chmiel, James F" sort="Chmiel, James F" uniqKey="Chmiel J" first="James F." last="Chmiel">James F. Chmiel</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pediatric Pulmonology, MS# 6006, Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, 44106, Cleveland, OH</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="ISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><imprint><publisher>Humana Press Inc</publisher><pubPlace>New York</pubPlace><date type="published" when="2008-12-01">2008-12-01</date><biblScope unit="volume">35</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="135">135</biblScope><biblScope unit="page" to="153">153</biblScope></imprint><idno type="ISSN">1080-0549</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1080-0549</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-inflammatory therapy</term><term>Corticosteroids</term><term>Cystic fibrosis</term><term>Ibuprofen</term><term>Inflammation</term><term>Lung</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Cystic fibrosis (CF) is an autosomal recessive disease affecting many organ systems. In the lung, the underlying ion transport defect in CF establishes a perpetuating cycle of impaired airway clearance, chronic endobronchial infection, and exuberant inflammation. The interrelated nature of these components of CF lung disease makes it likely that the most effective therapeutic strategies will include treatments of each of these. This chapter reviews the preclinical and clinical data focused on ways to better understand and particularly to limit inflammation in the CF airway. Anti-inflammatories are an attractive therapeutic target in CF with a proven ability to decrease the rate of decline in lung function. However, the inherent complexity of the inflammatory response combined with the obvious dependency on this response to contain infection and the side effect profiles of common anti-inflammatories have made identifying the most suitable agents challenging. Research continues to discover impairments in signaling events in CF that may contribute to the excessive inflammation seen clinically. Concurrent with these findings, promising new therapies are being evaluated to determine which agents will be most effective and well tolerated. Available data from studies commenced over the last two decades, which have generated both encouraging and disappointing results, are reviewed below.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Nichols, David P" sort="Nichols, David P" uniqKey="Nichols D" first="David P." last="Nichols">David P. Nichols</name></region><name sortKey="Chmiel, James F" sort="Chmiel, James F" uniqKey="Chmiel J" first="James F." last="Chmiel">James F. Chmiel</name><name sortKey="Chmiel, James F" sort="Chmiel, James F" uniqKey="Chmiel J" first="James F." last="Chmiel">James F. Chmiel</name><name sortKey="Konstan, Michael W" sort="Konstan, Michael W" uniqKey="Konstan M" first="Michael W." last="Konstan">Michael W. Konstan</name><name sortKey="Konstan, Michael W" sort="Konstan, Michael W" uniqKey="Konstan M" first="Michael W." last="Konstan">Michael W. Konstan</name><name sortKey="Nichols, David P" sort="Nichols, David P" uniqKey="Nichols D" first="David P." last="Nichols">David P. Nichols</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F30D95A8911972350FDACACAB2A66387CE5DEDCA
|texte= Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
}}
| This area was generated with Dilib version V0.6.33. |  |